Clinical Evidence

clinicaltrial.jpgVirulite CS® is clinically proven in a human trials conducted in the UK, to halve the healing time (healed in just 4.3 days) as compared to topically applied Aciclovir (Zovirax). The data, from a random, double blind, placebo controlled trial was published in the peer reviewed Journal of Clinical and Experimental Dermatology, Issues 26 & 31. 

Volunteers who took part in the clinical trials reported a significant reduction in the recurrence rate of cold sores at the treatment site as well as a rapid reduction in the discomfort and tingling normally associated with the cold sore eruption


Further human (in vivo) and laboratory (in vitro) trial and research is ongoing and results will be published in addition to the three papers already published on the Virulite treatment.

 ced-issue-26.png        ced-issue-31.pngimg-7610.png